Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

GABAergic dysfunction in mood disorders.

P Brambilla1, J Perez, F Barale

  • 1Biological Psychiatry Unit, IRCCS S Giovanni di Dio, Fatebenefratelli, Brescia, Italy. brambillapf@tiscalinet.it

Molecular Psychiatry
|July 31, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dissecting heterogeneity in cortical thickness abnormalities in major depressive disorder: a large-scale ENIGMA MDD normative modelling study.

bioRxiv : the preprint server for biology·2025
Same author

Affine diffractive beam dividers.

Journal of the Optical Society of America. A, Optics, image science, and vision·2024
Same author

The identification, assessment and management of difficult-to-treat depression: An international consensus statement.

Journal of affective disorders·2020
Same author

Microstructural white matter alterations in borderline personality disorder: A minireview.

Journal of affective disorders·2020
Same author

Disease-discordant twin structural MRI studies on affective disorders.

Neuroscience and biobehavioral reviews·2019
Same author

Intravenous valproate in the treatment of acute manic episode in bipolar disorder: A review.

Journal of affective disorders·2019
Same journal

Effects of family genetic risk scores and environmental factors on risk of schizophrenia and bipolar disorder.

Molecular psychiatry·2026
Same journal

Mitochondrial-inflammation crosstalk in major depressive disorder: molecular mechanisms and therapeutic implications.

Molecular psychiatry·2026
Same journal

Copy number variant scores are associated with cerebrovascular pathology in aging.

Molecular psychiatry·2026
Same journal

Opposite molecular sex correlations in tauopathy paralleled by motor and cognitive efficacy of davunetide in women.

Molecular psychiatry·2026
Same journal

Identification of hub genes involved in early-onset schizophrenia: from genetic susceptibility to predicted regulated gene expression.

Molecular psychiatry·2026
Same journal

Exercise-induced brain changes in cannabis use disorder: a longitudinal MRI study of a 12-week supervised HIIT program.

Molecular psychiatry·2026
See all related articles

Reduced gamma-aminobutyric acid (GABA) activity may contribute to mood disorders. Treatments that enhance GABAergic neurotransmission show promise for depression and bipolar disorder, suggesting a key role for this inhibitory neurotransmitter.

Area of Science:

  • Neuroscience
  • Psychiatry
  • Pharmacology

Background:

  • Mood disorders are complex neurological conditions with multifactorial etiologies.
  • Gamma-aminobutyric acid (GABA), the primary inhibitory neurotransmitter in the central nervous system (CNS), plays a crucial role in regulating neuronal excitability.
  • The GABAergic hypothesis of mood disorders suggests that dysfunction in GABAergic neurotransmission contributes to the pathophysiology of these conditions.

Purpose of the Study:

  • To review and synthesize available preclinical and clinical literature on GABAergic neurotransmission in mood disorders.
  • To evaluate the evidence supporting the GABAergic hypothesis of mood disorders.
  • To identify potential future research directions in this field.

Main Methods:

  • Literature review of preclinical studies (animal models) and clinical investigations (human patients).

Related Experiment Videos

  • Analysis of studies examining GABA levels, GABAergic receptor function, and the effects of GABA-modulating agents.
  • Synthesis of findings related to depression, unipolar, and bipolar disorder.

    • Main Results:

    • Preclinical studies indicate reduced GABA levels in animal models of depression.
    • Clinical studies report decreased plasma and cerebrospinal fluid (CSF) GABA levels in patients with mood disorders.
    • Pharmacological interventions targeting GABAergic systems (e.g., GABA agonists, antidepressants, mood stabilizers, electroconvulsive therapy) demonstrate efficacy in reversing depression-like behaviors and treating mood disorders.

    Conclusions:

    • The GABAergic hypothesis offers a complementary perspective to monoaminergic and serotonergic theories of mood disorders.
    • Evidence suggests that altered GABAergic activity is implicated in the pathophysiology of mood disorders.
    • Low GABAergic cortical function may represent a specific subtype or genetic susceptibility within the mood disorder population.